Correlation analysis between inflammatory biomarkers and significant clinical phenotypes of chronic obstructive pulmonary disease

Q3 Pharmacology, Toxicology and Pharmaceutics
E. Orlova, B. Kuzmichev, M. A. Orlov, I. Dorfman
{"title":"Correlation analysis between inflammatory biomarkers and significant clinical phenotypes of chronic obstructive pulmonary disease","authors":"E. Orlova, B. Kuzmichev, M. A. Orlov, I. Dorfman","doi":"10.18413/rrpharmacology.9.10004","DOIUrl":null,"url":null,"abstract":"Introduction: Chronic obstructive pulmonary disease (COPD) is the leading cause of mortality. Using the evidence obtained about various clinical phenotypes of patients with the same disease allowed us to expand our understanding of the treatment of COPD. Nowadays the only option for solving the problem will be the definition of the clinical phenotype of COPD, and the receipt of expanded data on its correlation with respiratory and other significant biomarkers.\nMaterials and methods: We analyzed the correlations between FKN, CRP and TBA-active lipid peroxidation products in 373 patients with various COPD phenotypes and 60 healthy volunteers. Enzyme immunoassay was used to study the levels of inflammatory biomarkers.\nResults: We have identified a statistically significant increase in the levels of inflammatory biomarkers in patients with COPD compared with the control. The FKN level in the group of patients with COPD was 1.3 ng/ml, which was higher (p<0.001) than in the control (FKN level of 0.3 ng/ml, p<0.001). The CRP level in patients with COPD was 27.8 mg/L, whereas in control the CRP level was 1.2 mg/L (p<0.001). The TBA-active lipid peroxidation products level in patients with COPD was 14.5 mmol/L, which was higher when compared to the control (p<0.001).\nDiscussion: The correlation analysis revealed very strong relationships between the levels of all the biomarkers studied. The highest values of the Kendall rank correlation coefficient (τ) were determined between the levels of all the inflammatory biomarkers in subgroups of patients with chronic bronchitis and mixed COPD phenotypes.\nConclusion: Detection of the COPD phenotype will help actively monitor the therapy of COPD exacerbations.\nGraphical Abstract\n","PeriodicalId":21030,"journal":{"name":"Research Results in Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Results in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18413/rrpharmacology.9.10004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is the leading cause of mortality. Using the evidence obtained about various clinical phenotypes of patients with the same disease allowed us to expand our understanding of the treatment of COPD. Nowadays the only option for solving the problem will be the definition of the clinical phenotype of COPD, and the receipt of expanded data on its correlation with respiratory and other significant biomarkers. Materials and methods: We analyzed the correlations between FKN, CRP and TBA-active lipid peroxidation products in 373 patients with various COPD phenotypes and 60 healthy volunteers. Enzyme immunoassay was used to study the levels of inflammatory biomarkers. Results: We have identified a statistically significant increase in the levels of inflammatory biomarkers in patients with COPD compared with the control. The FKN level in the group of patients with COPD was 1.3 ng/ml, which was higher (p<0.001) than in the control (FKN level of 0.3 ng/ml, p<0.001). The CRP level in patients with COPD was 27.8 mg/L, whereas in control the CRP level was 1.2 mg/L (p<0.001). The TBA-active lipid peroxidation products level in patients with COPD was 14.5 mmol/L, which was higher when compared to the control (p<0.001). Discussion: The correlation analysis revealed very strong relationships between the levels of all the biomarkers studied. The highest values of the Kendall rank correlation coefficient (τ) were determined between the levels of all the inflammatory biomarkers in subgroups of patients with chronic bronchitis and mixed COPD phenotypes. Conclusion: Detection of the COPD phenotype will help actively monitor the therapy of COPD exacerbations. Graphical Abstract
慢性阻塞性肺疾病炎症生物标志物与重要临床表型的相关性分析
慢性阻塞性肺疾病(COPD)是导致死亡的主要原因。利用获得的关于同一疾病患者不同临床表型的证据,使我们扩大了对COPD治疗的理解。目前,解决这一问题的唯一选择将是对COPD临床表型的定义,以及对其与呼吸和其他重要生物标志物相关性的扩展数据的接收。材料和方法:我们分析了373名不同COPD表型患者和60名健康志愿者的FKN、CRP和tba活性脂质过氧化产物的相关性。采用酶免疫分析法研究炎症生物标志物水平。结果:我们发现,与对照组相比,COPD患者的炎症生物标志物水平有统计学意义上的显著增加。COPD患者FKN水平为1.3 ng/ml,高于对照组(0.3 ng/ml, p<0.001)。COPD患者CRP水平为27.8 mg/L,而对照组CRP水平为1.2 mg/L (p<0.001)。COPD患者tba活性脂质过氧化产物水平为14.5 mmol/L,高于对照组(p<0.001)。讨论:相关分析显示,所研究的所有生物标志物水平之间存在很强的相关性。在慢性支气管炎和混合型COPD患者亚组中,所有炎症生物标志物的水平之间确定了肯德尔等级相关系数(τ)的最高值。结论:COPD表型的检测有助于积极监测COPD急性加重的治疗。图形抽象
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research Results in Pharmacology
Research Results in Pharmacology Medicine-Pharmacology (medical)
CiteScore
1.50
自引率
0.00%
发文量
32
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信